AR054515A1 - Composicion y procedimiento para producir oligomeros beta amiloides estables - Google Patents
Composicion y procedimiento para producir oligomeros beta amiloides establesInfo
- Publication number
- AR054515A1 AR054515A1 ARP060102727A ARP060102727A AR054515A1 AR 054515 A1 AR054515 A1 AR 054515A1 AR P060102727 A ARP060102727 A AR P060102727A AR P060102727 A ARP060102727 A AR P060102727A AR 054515 A1 AR054515 A1 AR 054515A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- amiloid
- procedure
- oligomers
- produce beta
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 230000002547 anomalous effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002296 dynamic light scattering Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a un procedimiento para la preparacion de un oligomero beta amiloide soluble estable y una composicion del mismo para usar como antígeno para la generacion de anticuerpos para el tratamiento de la enfermedad de Alzheimer y otros trastornos relacionados con la agregacion anomala de beta amiloide. El procedimiento que usa un pH en exceso de 7,0 y concentraciones elevadas de Abeta, opcionalmente incluye el uso de aniones divalentes o un disolvente inductor de hélice para formar los oligomeros. Los oligomeros Abeta solubles estables producidos mediante el procedimiento de la presente memoria descriptiva tienen un tamano de partícula de 10 a 100 nm. de diámetro, cuando se miden mediante una técnica de dispersion de luz dinámica, y un peso molecular de 100 a 500 kDa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69552605P | 2005-06-30 | 2005-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054515A1 true AR054515A1 (es) | 2007-06-27 |
Family
ID=37232911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102727A AR054515A1 (es) | 2005-06-30 | 2006-06-23 | Composicion y procedimiento para producir oligomeros beta amiloides estables |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100240868A1 (es) |
| EP (1) | EP1899372A1 (es) |
| JP (1) | JP2009500326A (es) |
| CN (1) | CN101218248A (es) |
| AR (1) | AR054515A1 (es) |
| AU (1) | AU2006266213A1 (es) |
| BR (1) | BRPI0612783A2 (es) |
| CA (1) | CA2611941A1 (es) |
| TW (1) | TW200726774A (es) |
| WO (1) | WO2007005359A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| CA2628703C (en) | 2005-11-30 | 2019-10-29 | Abbott Laboratories | Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| RS51723B2 (sr) | 2006-03-23 | 2018-03-30 | Bioarctic Neuroscience Ab | Poboljšana antitela selektivna za protofibrile i njihova primena |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| WO2009128772A1 (en) | 2008-04-14 | 2009-10-22 | Mivac Development Aktiebolag | Stable amyloid beta monomers and oligomers |
| WO2010105191A2 (en) * | 2009-03-12 | 2010-09-16 | The General Hospital Corporation | Antimicrobial compositions and methods of use therefore |
| CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
| WO2012009442A2 (en) | 2010-07-14 | 2012-01-19 | Merck Sharp & Dohme Corp. | Anti-addl monoclonal antibody and uses thereof |
| WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
| ES2496341T3 (es) * | 2011-10-04 | 2014-09-18 | Affiris Ag | Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica |
| DK3099296T3 (en) | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| PE20170768A1 (es) | 2014-07-10 | 2017-07-04 | Eisai Randd Man Co Ltd | Anticuerpos de union a protofibrillas ab mejorados |
| KR102614814B1 (ko) | 2017-05-15 | 2023-12-20 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 신경변성 질환 치료용 조성물 |
| CN110412294B9 (zh) * | 2019-08-07 | 2023-05-26 | 深圳市新产业生物医学工程股份有限公司 | 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法 |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN114106141A (zh) * | 2021-12-13 | 2022-03-01 | 中国科学院深圳先进技术研究院 | 一种β-淀粉样蛋白聚合物的制备方法及其产品和应用 |
| CN118027173A (zh) * | 2022-11-11 | 2024-05-14 | 深圳先进技术研究院 | 一种神经毒性β-淀粉样蛋白二聚体及其制备方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1200470B1 (en) * | 1999-08-04 | 2004-11-24 | The University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
-
2006
- 2006-06-22 TW TW095122532A patent/TW200726774A/zh unknown
- 2006-06-23 AR ARP060102727A patent/AR054515A1/es unknown
- 2006-06-26 AU AU2006266213A patent/AU2006266213A1/en not_active Abandoned
- 2006-06-26 JP JP2008519443A patent/JP2009500326A/ja not_active Withdrawn
- 2006-06-26 US US11/922,528 patent/US20100240868A1/en not_active Abandoned
- 2006-06-26 WO PCT/US2006/024744 patent/WO2007005359A1/en not_active Ceased
- 2006-06-26 CA CA002611941A patent/CA2611941A1/en not_active Abandoned
- 2006-06-26 EP EP06785555A patent/EP1899372A1/en not_active Withdrawn
- 2006-06-26 CN CNA2006800236696A patent/CN101218248A/zh active Pending
- 2006-06-26 BR BRPI0612783A patent/BRPI0612783A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100240868A1 (en) | 2010-09-23 |
| AU2006266213A1 (en) | 2007-01-11 |
| BRPI0612783A2 (pt) | 2016-11-29 |
| JP2009500326A (ja) | 2009-01-08 |
| CA2611941A1 (en) | 2007-01-11 |
| EP1899372A1 (en) | 2008-03-19 |
| CN101218248A (zh) | 2008-07-09 |
| WO2007005359A1 (en) | 2007-01-11 |
| TW200726774A (en) | 2007-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054515A1 (es) | Composicion y procedimiento para producir oligomeros beta amiloides estables | |
| Sabri et al. | Dual activity of rose bengal functionalized to albumin-coated lanthanide-doped upconverting nanoparticles: targeting and photodynamic therapy | |
| Zhang et al. | An injectable dipeptide–fullerene supramolecular hydrogel for photodynamic antibacterial therapy | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
| ES2721898T3 (es) | Formulaciones estables para liofilizar partículas terapéuticas | |
| AR084158A1 (es) | Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas | |
| CY1118760T1 (el) | Τροποποιημενα αντισωματα εναντι il-23 | |
| CL2018000320A1 (es) | Coadyuvantes basados en aceite (divisional de solicitud 201600650) | |
| CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
| CY1114577T1 (el) | Αποτροπη και θεραπεια υπο-κλινικης pcvd | |
| WO2014135282A8 (en) | Amatoxin derivatives | |
| DOP2011000199A (es) | Compuestos heterociclocos y metodos de uso | |
| CY1118714T1 (el) | Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2 | |
| GT201100127A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1 | |
| SI1485080T1 (sl) | Uporaba adapalena za zdravljenje dermatoloških motenj | |
| NO20073722L (no) | Farmasoystiske sammensetniger omfattende bendamustin | |
| BR112016024619A2 (pt) | conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer | |
| CY1115082T1 (el) | Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων | |
| CY1111757T1 (el) | Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α | |
| CY1114952T1 (el) | Ενεργοποιητες θειενο[2,3-b]πυριδινοδιονης της αμρκ και θεραπευτικες χρησεις αυτων | |
| CL2008003473A1 (es) | Compuestos derivados de fenilpiperidina sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso en el tratamiento del trastorno cardiovasculares, tromboembolicos y tumorales; usos in vitro. | |
| UY40003A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CY1110046T1 (el) | Γαβοξαδολη για τη θεραπεια της καταθλιψης και αλλων συναισθηματικων διαταραχων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |